Press release
Neupogen (filgrastim) Market Overview, Current Trends, and Key Player Analysis
Neupogen (filgrastim) Market
Forecasted Market Size of Neupogen (filgrastim) by 2030
The Neupogen (filgrastim) market is anticipated to reach a value of $1.81 million by 2030, growing at a compound annual growth rate (CAGR) of 5.2%. This steady rise is largely fueled by an increasing incidence of cancer cases, wider adoption of biosimilar drugs, expansion in outpatient oncology services, enhanced availability of biologic treatments, and a strong focus on preventing infections. Key trends supporting this growth include greater use of supportive care therapies in oncology, broader management strategies for chemotherapy-induced neutropenia, rising acceptance of biologic growth factors, a shift toward outpatient care for neutropenia, and an uptick in biosimilar usage.
Download a free sample of the neupogen (filgrastim) market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Prominent Companies Leading the Neupogen (filgrastim) Market
Within the Neupogen (filgrastim) space, Amgen Inc. stands out as a major player driving market development. The company's innovations and product offerings significantly influence market dynamics and competitive positioning.
Emerging Trends Impacting the Neupogen (filgrastim) Industry
Innovations in the market are largely centered around the development of cost-effective filgrastim biosimilars, which aim to provide an accessible alternative for patients undergoing chemotherapy-induced neutropenia treatment. These biosimilars closely resemble the original Neupogen in terms of safety, efficacy, and structure, helping to stimulate neutrophil production in affected patients. For example, in September 2024, U.S.-based Tanvex BioPharma secured FDA approval for Nypozi (filgrastim-txid), a biosimilar referencing Amgen's Neupogen. Nypozi was one of three biosimilars approved by the FDA on the same day, contributing to a total of 55 biosimilars authorized in the United States by June 2024. This medication is indicated to reduce infection risk manifested as febrile neutropenia in patients with non-myeloid cancers receiving myelosuppressive chemotherapy drugs.
View the full neupogen (filgrastim) market report:
https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Key Segmentation Categories in the Neupogen (filgrastim) Market
The market analysis segments Neupogen (filgrastim) based on several important criteria:
1) Drug Type: Biologic and Biosimilar
2) Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, and Other uses
3) Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
These categories help clarify the market's structure and provide deeper insight into areas of demand and distribution.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neupogen (filgrastim) Market Overview, Current Trends, and Key Player Analysis here
News-ID: 4492653 • Views: …
More Releases from The Business Research Company
Segment Analysis and Major Growth Areas in the Menquadfi Market
The Menquadfi vaccine market is gaining significant traction as global health priorities shift toward enhanced immunization strategies and disease prevention. With growing awareness around the importance of booster doses and broader vaccine coverage, this sector is poised for substantial growth in the coming years. Let's explore the forecasted market expansion, key industry players, segmentation details, and emerging trends shaping the Menquadfi landscape.
Projected Growth Outlook for the Menquadfi Market Through 2030…
Market Driver Insights: The Impact of Recent Advancements on the Lyumjev Market
Understanding the future prospects of the Lyumjev market offers valuable insight into how diabetes treatment is evolving with new technologies and patient-focused care. As healthcare providers and patients increasingly seek more effective and convenient options, the market is positioned for significant growth by 2030. Let's explore the factors driving this expansion, the major players involved, and the detailed segmentation shaping the market landscape.
Growth Outlook and Market Size Projections for Lyumjev…
In-Depth Examination of Segments, Industry Developments, and Key Competitors in …
The Lumizyme market is gaining attention as advancements in rare disease treatments continue to shape its future. With increasing investments and evolving healthcare practices, the outlook through 2030 reflects substantial growth potential. Below, we explore the market's size projection, key players, emerging trends, and detailed segmentation.
Long-Term Growth Prospects for the Lumizyme Market Size Through 2030
The anticipated rise in the Lumizyme market over the coming years stems from several factors.…
Leading Companies Reinforcing Their Presence in the Libmeldy Market
The Libmeldy market is gaining significant attention as advancements in gene therapy and rare disease research accelerate. With growing support from regulatory bodies and increasing investments, this market is set to evolve rapidly. Let's explore the anticipated market size, leading companies, key trends, and segmentation that define Libmeldy's landscape.
Libmeldy Market Size Outlook Through 2030
The predicted expansion of the Libmeldy market by 2030 is driven by multiple factors. These include…
More Releases for Neupogen
Neupogen Market Expansion Fueled by Cancer Supportive Care and Neutropenia Treat …
The qualitative latest Research report (2025-2032) on the Neupogen Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/8115
Focused on growth and future…
Neupogen Market Set to Witness Significant Growth from 2025 to 2032, Highlightin …
The Neupogen Market 2025 Forecast to 2032" research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Neupogen industry, as well as predicted future growth, technological advancements, investment prospects, market economics, and financial…
Neupogen Market Surging as Biosimilars Take Over and Supportive Cancer Care Expa …
The Global Neupogen Market is expected to decline from USD 89.2 Mn in 2025 to USD 30.5 Mn by 2032, with a negative CAGR of -14.2% over the forecast period.
The latest Neupogen Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2025 and 2032. It analyzes market size, revenue, production, and CAGR using validated…
Comprehensive Neupogen (filgrastim) Market Insights: Forecasting Size, Growth, a …
How Are the key drivers contributing to the expansion of the neupogen (filgrastim) market?
The advancement of the neupogen (filgrastim) market is anticipated due to an escalating occurrence of diverse diseases. Diseases refer to irregularities in bodily functions or structures that manifest particular symptoms and commonly impact specific areas, generally induced by environmental factors, lifestyle choices, infections, or genetics. The escalating prevalence of diseases is propelled by elements like an aging…
Neupogen (filgrastim) Market Outlook 2025-2034: Key Trends, Growth Drivers, and …
How Big Is the Neupogen (filgrastim) Market Expected to Be, and What Will Its Growth Rate Be?
In the recent past, the market size of neupogen (filgrastim) has seen a significant surge. The sector is expected to boost from $1,330.69 million in 2024, reaching up to $1,404.70 billion in 2025 with a compound annual growth rate (CAGR) of 5.6%. Factors such as a surge in cancer cases, increased understanding of chemotherapy-induced…
Global Filgrastim Biosimilar Market is Expected to Grow at Rapid Pace With Stron …
InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on ' Global Filgrastim Biosimilar Market Assessment – Revenue Forecast, Clinical Trial/Pipeline Analysis, Brand/Originator Drug Historic Revenue and Forecast Till 2027'
Request for ToC/Proposal: https://bit.ly/2UfBXlC
Filgrastim is G-CSF that stimulates bone marrow to produce more neutrophils. The drug was developed by Amgen and marketed under the trade name of Neupogen. It was approved in the U.S. by Food Drug and Administration…
